PEB - Pacific Edge Ltd

[psychic]

They have the proof, they have affirmations by the AUA, they have a methodology/ IP that no one in their right mind would want to spend millions on trying to beat, they have a sales force in the USA, so they better have some very good reason to want to tap existing and new shareholders for $70 mio. The only reason I can think of, and would like to think of, is a massive uptake in demand

Disagree, proof is what is still said to be needed, the AUA do not support it, there is a world of competition and development in this field.

The tests are not covered by US Insurers and I suspect, only in a small way as an adjunct through CMS and KP.

The last financial update did not support uptake of any scale and I will suggest that neither will the next.
The shares are absurdly priced for the evidence to hand and, as I have argued in the past, have got here on the back of four announcements that simply exaggerate reality.

Why might they need $70m from the Aussie? Because they will need this w/cap if to continue over the next several years. A cash raise after the Sept results come out will be awkward, and much better if they can do it while the SP is over the moon.

The ASX has a world of experience when it comes to dealing with liars at the top of a hole, the market there will not be so easily duped.

[Rawz]

The ASX has a world of experience when it comes to dealing with liars at the top of a hole, the market there will not be so easily duped.

Plexure managed to pull a quick one on investors when listing on the ASX. Raised heaps of cash only to see the sp halve because the business didn't deliver on its promises. Now it's raising heaps more at half the price.

Hope PEB delivers

[Balance]

Now that PEB has applied for ASX listing and showed its hand by initiating a $70m $1.20 sp CR - what follows from hereon in will tell us a lot about how the Australian institutions and investors view PEB as an investment.

Will the CR go ahead? At what sp and for how much?

The Australians are definitely more savvy when it comes to biomed & biotech stocks - they have many success stories to relate to and there is real depth in the market.

Watching with interest & hanging on to some of my shareholding.

[psychic]

The Aussie Healthcare market hasn't run with Cxbladder, odd that they think the insto's might.

[Minerbarejet]

The Aussie Healthcare market hasn't run with Cxbladder, odd that they think the insto's might.

Aussies mate, no surprises there.

[Harrie]

Disagree, proof is what is still said to be needed, the AUA do not support it, there is a world of competition and development in this field.

The tests are not covered by US Insurers and I suspect, only in a small way as an adjunct through CMS and KP.

The last financial update did not support uptake of any scale and I will suggest that neither will the next.
The shares are absurdly priced for the evidence to hand and, as I have argued in the past, have got here on the back of four announcements that simply exaggerate reality.

Why might they need $70m from the Aussie? Because they will need this w/cap if to continue over the next several years. A cash raise after the Sept results come out will be awkward, and much better if they can do it while the SP is over the moon.

The ASX has a world of experience when it comes to dealing with liars at the top of a hole, the market there will not be so easily duped.

One may possibly assume that with a name like psychic a little more understanding of human psychology would be a given. Motivation for different forms of human behavior comes down to basic self preservation which is manifested in greed, power, denial, distraction, lies, etc, anything to maintain or enhance ones own survival in an unequal world.
Vested interests are one of those manifestations of survival. Professional bodies act to protect their members from economic loss even if this is against the interests of those who would most benefit from a better solution to a problem either health or financial wise.
You say there is a world of competition in this field. Maybe, but the world is waiting for years of trials and data to prove that whatever this new test may be, why it would be more predictive than something that is already proven over several years of data collection. The AUA is already begrudgingly accepting Cxbladder as being more effective in detection of bladder cancer than a $4 grand invasive biopsy. They certainly are not shouting from the rooftops about it, but why would they when most of their members are on the cystoscopy gravy train.
Insurance companies are not that stupid as to continually pay out on cystoscopys when they can pay around 80% less for an alternative with a better NPV. Its just a matter of time and education which is more likely to come about through consumers, similar to PCR tests for HPV, nasal swap tests vs saliva tests etc

[Minerbarejet]

For those who may be interested here is a recently shared link for your perusal.

Its pretty big so it may take a while.

cxBladder is mentioned (eventually)


https://pc.icurology.org/DOIx.php?id...1/icu.20210194

[psychic]

One may possibly assume that with a name like psychic a little more understanding of human psychology would be a given. Motivation for different forms of human behavior comes down to basic self preservation which is manifested in greed, power, denial, distraction, lies, etc, anything to maintain or enhance ones own survival in an unequal world.
Vested interests are one of those manifestations of survival. Professional bodies act to protect their members from economic loss even if this is against the interests of those who would most benefit from a better solution to a problem either health or financial wise.
You say there is a world of competition in this field. Maybe, but the world is waiting for years of trials and data to prove that whatever this new test may be, why it would be more predictive than something that is already proven over several years of data collection. The AUA is already begrudgingly accepting Cxbladder as being more effective in detection of bladder cancer than a $4 grand invasive biopsy. They certainly are not shouting from the rooftops about it, but why would they when most of their members are on the cystoscopy gravy train.
Insurance companies are not that stupid as to continually pay out on cystoscopys when they can pay around 80% less for an alternative with a better NPV. Its just a matter of time and education which is more likely to come about through consumers, similar to PCR tests for HPV, nasal swap tests vs saliva tests etc

Harrie. Thanks for the insights! My understanding is that an office cystoscopy costs around $350- $650. A single Cxbladder test costs more in the US. Not so in NZ and perhaps this is why it has been adopted here? Happy to be corrected on this?

Also, need to be careful with that NPV. It does not apply to all Cxbladder tests. Each test is designed for a certain stage of diagnosis or management.

I have followed the coverage decisions of the major US Insurers for years. No sign that they are warming to Cxbladder yet.

[psychic]

**CMS reimbursement schedule 2021 $234.21 for office cystoscopy.
Harrie - the AUA do not "begrudgingly accept Cxbladder" at all. They say Urinary biomarkers should not be used in place of cystoscopy.

[Ggcc]

Now that PEB has applied for ASX listing and showed its hand by initiating a $70m $1.20 sp CR - what follows from hereon in will tell us a lot about how the Australian institutions and investors view PEB as an investment.

Will the CR go ahead? At what sp and for how much?

The Australians are definitely more savvy when it comes to biomed & biotech stocks - they have many success stories to relate to and there is real depth in the market.

Watching with interest & hanging on to some of my shareholding.

My guess is that if they ask for $70 million there must be a good reason. Either sales have far exceeded what they thought was going to happen and that need to expand their sales and processing centre.